국내 혈액질환 환자에서 침습성 아스페르길루스증의 구제치료로서 Voriconazole의 효과와 안전성
Efficacy and Safety Profile of Voriconazole as Salvage Therapy for Invasive Aspergillosis with Hematologic Diseases in Korea
1
조회
0
다운로드
2
인용
0
참고문헌
키워드
초록
Background: Invasive aspergillosis (IA) is associated with significant morbidity and mortality in patients with hematologic malignancies. We investigated the efficacy and safety of voriconazole (VCZ) when used as salvage therapy for IA in Korean adults with hematologic malignancies who had not responded to prior antifungal therapy. Materials and Methods: We retrospectively reviewed data, collected from January 2007 to October 2008, from patients with proven or probable cases of IA. All were probable IA cases, except for one proven case. All cases were refractory or intolerant to antifungal therapy prior to administration of VCZ. Efficacy and safety were assessed in patients treated with VCZ for more than 3 days and for more than one dose, respectively. A favorable response [complete (CR) or partial (PR)] was defined by significant improvement of all clinical symptoms, signs, and radiologic abnormalities. Results: Fifty patients who met the inclusion criteria were enrolled. There were 27 male and 23 female patients with mean age of 44.4 years (range, 15-65 years). Underlying diseases were acute leukemia (35 cases), chronic myelogenous leukemia (4 cases), myelodysplastic syndrome (3 cases), lymphoma (3 cases) and other hematologic diseases (5 cases). Twenty-two patients had received chemotherapy and 13 patients had undergone hematopoietic stem cell transplantation. The lung was the main infection site (94%) followed by the sinus (6%). Amphotericin B deoxycholate alone was the most frequent previous antifungal therapy. The mean duration of antifungal therapy prior to VCZ therapy was 13.9±8.8 days (2-44 days). The median duration of VCZ therapy was 19 days (interquartile range, 49 days). Sixteen patients (32.0%) showed favorable responses (CR:PR=8:8) at the end of VCZ therapy. The numbers of patients with stable disease, progression and death were, 6 (12%), 6 (12%) and 22 (44%) respectively. Most of those with unfavorable responses had relapsed underlying malignancies or refractory graft versus host diseases. Twelve patients developed drug-related adverse events but only one patient stopped VCZ treatment prematurely. Conclusions: VCZ demonstrated an acceptable level of toxicity in patients with hematologic malignancies but further studies are required to prove its efficacy as salvage therapy.
Abstract
Background: Invasive aspergillosis (IA) is associated with significant morbidity and mortality in patients with hematologic malignancies. We investigated the efficacy and safety of voriconazole (VCZ) when used as salvage therapy for IA in Korean adults with hematologic malignancies who had not responded to prior antifungal therapy. Materials and Methods: We retrospectively reviewed data, collected from January 2007 to October 2008, from patients with proven or probable cases of IA. All were probable IA cases, except for one proven case. All cases were refractory or intolerant to antifungal therapy prior to administration of VCZ. Efficacy and safety were assessed in patients treated with VCZ for more than 3 days and for more than one dose, respectively. A favorable response [complete (CR) or partial (PR)] was defined by significant improvement of all clinical symptoms, signs, and radiologic abnormalities. Results: Fifty patients who met the inclusion criteria were enrolled. There were 27 male and 23 female patients with mean age of 44.4 years (range, 15-65 years). Underlying diseases were acute leukemia (35 cases), chronic myelogenous leukemia (4 cases), myelodysplastic syndrome (3 cases), lymphoma (3 cases) and other hematologic diseases (5 cases). Twenty-two patients had received chemotherapy and 13 patients had undergone hematopoietic stem cell transplantation. The lung was the main infection site (94%) followed by the sinus (6%). Amphotericin B deoxycholate alone was the most frequent previous antifungal therapy. The mean duration of antifungal therapy prior to VCZ therapy was 13.9±8.8 days (2-44 days). The median duration of VCZ therapy was 19 days (interquartile range, 49 days). Sixteen patients (32.0%) showed favorable responses (CR:PR=8:8) at the end of VCZ therapy. The numbers of patients with stable disease, progression and death were, 6 (12%), 6 (12%) and 22 (44%) respectively. Most of those with unfavorable responses had relapsed underlying malignancies or refractory graft versus host diseases. Twelve patients developed drug-related adverse events but only one patient stopped VCZ treatment prematurely. Conclusions: VCZ demonstrated an acceptable level of toxicity in patients with hematologic malignancies but further studies are required to prove its efficacy as salvage therapy.
참고문헌 (26)
- Maschmeyer G, "Invasive aspergillosis: epidemiology, diagnosis and management in immunocompromised patients", Drugs, 67, pp.1567~1601 (2007)
- Herbrecht R, "Invasive Fungal Infections Group of the European Organisation for Research and Treatment of Cancer and the Global Aspergillus Study Group. Voriconazole versus amphotericin B for primary therapy of invasive aspergillosis", N Engl J Med, 347, pp.408~415 (2002)
- Cornely OA, "AmBiLoad Trial Study Group. Liposomal amphotericin B as initial therapy for invasive mold infection: a randomized trial comparing a high-loading dose regimen with standard dosing (AmBiLoad trial)", Clin Infect Dis, 44, pp.1289~1297 (2007)
- Scott LJ, "Voriconazole: a review of its use in the management of invasive fungal infections", Drugs, 67, pp.269~298 (2007)
- Walsh TJ, "Infectious Diseases Society of America. Treatment of aspergillosis: clinical practice guidelines of the infectious diseases society of America", Clin Infect Dis, 46, pp.327~360 (2008)
- Peman J, "Voriconazole in the management of nosocomial invasive fungal infections", Ther Clin Risk Manag, 2, pp.129~158 (2006)
- Ascioglu S, "Invasive Fungal Infections Cooperative Group of the European Organization for Research and Treatment of Cancer; Mycoses Study Group of the National Institute of Allergy and Infectious Diseases. Defining opportunistic invasive fungal infections in immunocompromised patients with cancer and hematopoietic stem cell transplants: an international consensus", Clin Infect Dis, 34, pp.7~14 (2002)
- Hughes WT, "2002 guidelines for the use of antimicrobial agents in neutropenic patients with cancer", Clin Infect Dis, 34, pp.730~751 (2002)
- Segal BH, "Defining responses to therapy and study outcomes in clinical trials of invasive fungal diseases: Mycoses Study Group and European Organization for Research and Treatment of Cancer consensus criteria", Clin Infect Dis, 47, pp.674~683 (2008)
- Naranjo CA, "A method for estimating the probability of adverse drug reactions", Clin Pharmacol Ther, 30, pp.239~245 (1981)
- Perfect JR, "Voriconazole treatment for lesscommon, emerging, or refractory fungal infections", Clin Infect Dis, 36, pp.1122~1131 (2003)
- Baden LR, "Salvage therapy with voriconazole for invasive fungal infections in patients failing or intolerant to standard antifungal therapy", Transplantation, 76, pp.1632~1637 (2003)
- Denning DW, "Efficacy and safety of voriconazole in the treatment of acute invasive aspergillosis", Clin Infect Dis, 34, pp.563~571 (2002)
- Maertens J, "Caspofungin Salvage Aspergillosis Study Group. Efficacy and safety of caspofungin for treatment of invasive aspergillosis in patients refractory to or intolerant of conventional antifungal therapy", Clin Infect Dis, 39, pp.1563~1571 (2004)
- Walsh TJ, "Treatment of invasive aspergillosis with posaconazole in patients who are refractory to or intolerant of conventional therapy: an externally controlled trial", Clin Infect Dis, 44, pp.2~12 (2007)
- Dockrell DH, "Salvage therapy for invasive aspergillosis", J Antimicrob Chemother, Suppl 1, pp.i41~i44 (2008)
- 최수미, "국내 혈액질환 환자에서 침습성 진균 감염의 구제치료로서 Caspofungin의 효과와 안전성", Infection and Chemotherapy, 37(5), pp.247~254 (2005), 대한감염학회
- Walsh TJ, "National Institute of Allergy and Infectious Diseases Mycoses Study Group. Voriconazole compared with liposomal amphotericin B for empirical antifungal therapy in patients with neutropenia and persistent fever", N Eng J Med, 346, pp.225~234 (2002)
- Almyroudis NG, "Issues related to the design and interpretation of clinical trials of salvage therapy for invasive mold infection", Clin Infect Dis, 43, pp.1449~1455 (2006)
- 강철인, "침습성 아스페르길루스증의 발생 양상과 치료결과", Infection and Chemotherapy, 34(3), pp.160~166 (2002), 대한감염학회
- Nivoix Y, "Factors asso-ciated with overall and attributable mortality in invasive aspergillosis", Clin Infect Dis, 47, pp.1176~1184 (2008)
- Muijsers RB, "Voriconazole: in the treatment of invasive aspergillosis", Drugs, 62, pp.2655~2664 (2002)
- Pascual A, "Voriconazole therapeutic drug monitoring in patients with invasive mycoses improves efficacy and safety outcomes", Clin Infect Dis, 46, pp.201~211 (2008)
- Boyd AE, "Keevil BG, Denning DW. Adverse reactions to voriconazole", Clin Infect Dis, 39, pp.1241~1244 (2004)
- Connelly LM, "Retrospective chart reviews", Medsurg Nurs, 17, pp.322~323 (2008)
- Localio AR, "Identifying adverse events caused by medical care: Degree of physician agreement in a retrospective chart review", Ann Intern Med, 125, pp.457~464 (1996)